SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the global nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market which is also expected to be valued at $30 billion by 2030. SOHM’s strategic approach has seen it bring experts on board, some of whom have previously served in advisory capacities within the company and have a good understanding of its ethos, vision, and overall approach to solving client problems.
On September 11, the company announced the appointment of Wm. Dewey Rushing as the new Vice President-Quality. Mr. Rushing previously served as an Advisory Board member at the company since 2022. His years of experience in cell therapy IND readiness, quality systems audits, aseptic processing, and cGMP compliance and regulation make him a valuable asset to the company, mainly as it explores the next steps for growth (https://ibn.fm/YQ86u).
While announcing his appointment, Baron Night, SOHM’s President and CEO, lauded Mr. Rushing’s value to the company, noting how instrumental he has been in providing his expertise on validation and compliance issues.
“SOHM has appointed him [Mr. Rushing] as the Vice President of Quality, recognizing his exceptional qualifications and experience in pharmaceutical quality validation and cGMP compliance,” noted Mr. Night.
Mr. Rushing’s appointment follows the recent appointment of Dr. Krishna Bhat (MD, Ph.D., FACC as the company’s new Chief Medical Advisor and Dr. David Aguilar (Ph.D.) as the new Chief Operating Officer (“COO”) (https://ibn.fm/ZFLRS). These are all in a bid to strengthen the company’s governing team while propping it for success as it expands on the most ambitious phase of the company’s progression.
SOHM also recently signed a letter of intent (“LOI”) to acquire A Binding Based Integrating Enzyme (“ABBIE”) stem cell disruptive technology and patents from CGA Intellectual Holdings Inc. This would allow it to create novel products and solutions in the regenerative medicine and cosmeceutical industries, a useful asset in SOHM’s growing portfolio (https://ibn.fm/4o6Fk). The three appointments will be integral in leveraging this product, bringing it to market, and even utilizing it to create novel products and solutions for customers.
SOHM envisions a future where it evolves into a prominent global corporation with corresponding market reach, while maintaining its fundamental core values. So far, it is on track to extend its export portfolio to 11 countries, a milestone that reflects its growing expertise. These recent appointments build on the success and the momentum gained so far, and management is increasingly confident about anticipated developments and opportunities.
For more information, visit the company’s website at www.SOHM.com.
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately…
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…
Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in…
Scientists have found that keeping circadian rhythms, the variations in body processes during the course…
While many capitalization structures are diluted in the landscape of over-the-counter (“OTC”) markets, Earth Science…
The United States has formally communicated its immediate withdrawal from the World Health Organization (WHO), denying…